Biotechnology Assets, S.A. (BST:041)
0.1800
-0.0300 (-14.29%)
At close: Dec 5, 2025
Biotechnology Assets Company Description
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally.
It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VACC-ZERA technology, a tool to generate recombinant proteins in microparticles suited for therapeutic and prophylactic adjuvant free vaccines administered as DNA vaccines; and CLICK’N CUT, a tool to obtain tag-less proteins in a one-step process based on intein affinity, as well as Zebrafish assays.
The company is based in Cádiz, Spain.
Biotechnology Assets, S.A.
| Country | Spain |
| Industry | Pharmaceutical Preparations |
| Employees | 34 |
| CEO | Jaime Feced Rubio |
Contact Details
Address: Av. del Desarrollo Tecnológico, 11 Cádiz, 11591 Spain | |
| Phone | 34 856 06 06 03 |
| Website | biatgroup.com |
Stock Details
| Ticker Symbol | 041 |
| Exchange | Stuttgart Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jaime Feced Rubio | Chief Executive Officer |